The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs and comes ...
The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and ...
Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...
A new generation of anti-obesity drugs aims for greater effectiveness, fewer side effects, and more convenience.
The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...
In November, Amneal received FDA approval for exenatide, its first generic injectable glucagon-like peptide-1 (GLP-1) agonist ...
Biosimilars have also made inroads among generic suppliers. But development is lengthy and expensive. McKinsey estimates that it costs $100 to $300 million to develop a biosimilar and that it takes ...
A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...
Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...
Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...
Dr. Philip A. Chan joined GoLocal to discuss the new wave of weight loss drugs and their implications for fighting obesity as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback